For more than two years, Smulyan, 61, has been unflaggingly optimistic during quarterly conference calls. But since early 2007, Emmis’ stock has fallen 84 percent, shrinking the company’s stock market value from $307 million to $48 million. The troubles have cast uncertainty over one of Indianapolis’ highest-profile businesses.
Interactive Intelligence Inc. is enduring a serious stock slump. Its battered shares are trading around $10, about $20
off their 52-week peak. Yet CEO Don Brown remains so bullish on the software maker that he’s authorized a $10 million stock
buyback.
Most public companies say they tie executive compensation to performance, but an IBJ review of pay data from 65 Indiana-based
firms shows otherwise. Last year, more than two-thirds of Indiana-based public companies saw their share prices decline, yet
many continued to award eye-popping compensation to their executives.
Angela Braly, Wayne DeVeydt and the rest of the top brass at WellPoint Inc. face wrath over the company’s recent stock swoon
from a new group: ex-employees. Four former WellPoint workers have filed lawsuits against the Indianapolis-based health insurance
giant over the losses its 401(k) retirement plan suffered in March when the company slashed its profit forecast for the year.
In just over one quarter, shares of Celadon Group lost nearly half their value as profitable cargo got harder to find in a
slowing economy. The stock closed at $9.13 on Dec. 19, down from nearly $17 in late August.
The Indianapolis Indians are rewarding stockholders in the franchise following a season in which revenue and profit grew,
thanks to significant increases in ticket, concession and merchandise sales. The higher profit fueled a 75-percent dividend
increase this year and an increase of more than $6,500 in the franchise’s standing offer to repurchase shares.
The July 21 announcement by Lilly Endowment Inc. that it will reduce its holdings in Eli Lilly and Co. by $2 billion will have enormous repercussions. It’s meant to decrease volatility in the endowment’s assets, but it also erodes one of Lilly’s key antitakeover provisions.
